Reproductive system status and the algorithm to solve fertility issues in men with cystic fibrosis

Cover Page


Cite item

Full Text

Abstract

Rationale: Cystic fibrosis (CF) is a common hereditary disease related to the CFTR gene mutations and characterized by progression and multiple system involvement (primarily of the digestive tract and / or pulmonary system). Most men with CF are infertile. Due to new therapeutic options, the life expectancy of CF patients has increased, with reproductive issues becoming relevant.

Aim: A multifaceted assessment of the reproductive system status and fertility in male patients with CF and improvement of the strategies to resolve their reproduction issues.

Materials and methods: This cohort prospective study was performed 2006 to 2018 and included 81 unrelated Russian male patients with confirmed CF, aged from 15 to 69 years (mean age 25.6 ± 7.9 years). Forty two (42) patients had pancreatic sufficient and 39 pancreatic insufficient CF. The patients underwent clinical, andrological, laboratory and instrumental examination (scrotal ultrasonography, standard and biochemical semen examination and hormone levels).

Results: Reproductive disorders and semen abnormalities found in CF patients varied from preserved fertility to infertility. The following andrological abnormalities were found: delayed puberty (48%), urological disorders (26%), uni- or bilateral testicular hypoplasia (42%), diffuse lesions and cysts of the epididymis (70%), diffuse lesions /calcifications of the prostate (50%), and decreased testosterone levels (24.2%). Azoospermia was diagnosed in 87.5% of the patients, “moderate” or “mild” pathozoospermia (oligo-/astheno-/teratozoospermia) in 11.1%, and normozoospermia in 1.4% of the patients. There were significant differences between the patients with pancreatic sufficient and pancreatic insufficient CF in the ejaculate volume (1.4 ± 1.5 ml vs. 0.6 ± 0.5 ml; р = 0.006), ejaculate pH (6.7 ± 0.7 vs. 6.1 ± 0.4; р < 0.0001), and sperm concentration (19.6 ± 56.0 Mio/mL vs. 0.001 ± 0.008 Mio/ mL; p = 0.011). Normal ejaculate volume was more frequent (21.1% vs 14.7%; p > 0.05) in patients under the age of 25. No bilateral obstruction of vas deferens was found in 71.4% patients with 3849+10kbC>T mutation. There was a significant difference (p < 0.00001) in the frequency of 3849+10kbC>T mutation between the patients with vas deferens obstruction (9.5%) and without it (93.8%). We developed an algorithm to resolve infertility issues (including assisted reproductive technologies) in male CF patients depending on their fertility / presence and type of pathozoospermia and some other factors that may influence the conception and CF risk in the offspring. We also suggested practical recommendations for the andrological assessment, maintenance of reproductive health, and planning of childbirth in these patients.

Conclusion: Male CF patients require a multifaceted assessment of their reproductive system. The prognosis of their reproductive functions, the strategy to maintain their reproductive health and making a decision on childbirth depends on the CF type, the CFTR genotype, the results of semen analysis, and the patient’s age. Pancreatic sufficient CF type, 3849+10kbС>T mutation of the CFTR gene and younger age are favorable factors for potential maintenance of vas deferens patency and male fertility in CF patients.

About the authors

S. A. Repina

Medical Genetic Science Center

Author for correspondence.
Email: repina@med-gen.ru

Svetlana A. Repina – MD, Geneticist, Medical Services Department 

1 Moskvorech'e ul., Moscow, 115522

Россия

S. A. Krasovskiy

Medical Genetic Science Center;
Federal Pulmonology Research Institute

Email: fake@neicon.ru

Stanislav A. Krasovskiy – MD, PhD, Senior Research Fellow, Clinical and Consulting Department of Cystic Fibrosis Medical Genetic Science Center; Laboratory of Cystic Fibrosis Federal Pulmonology Research Institut

1 Moskvorech'e ul., Moscow, 115522, 

32/4 11-ya Parkovaya ul., Moscow, 105077

Россия

G. V. Shmarina

Medical Genetic Science Center

Email: fake@neicon.ru

Galina V. Shmarina – MD, PhD, Leading Research Fellow, Laboratory of Molecular Biology  

1 Moskvorech'e ul., Moscow, 115522

Россия

M. I. Shtaut

Medical Genetic Science Center

Email: fake@neicon.ru

Maria I. Shtaut – MD, Research Fellow, Laboratory of Genetics of Reproductive Disorders

1 Moskvorech'e ul., Moscow, 115522

Россия

E. K. Zhekayte

Medical Genetic Science Center;
Moscow Regional State Referral Center for Children

Email: fake@neicon.ru

Elena K. Zhekayte – MD, Research Fellow, Clinical and Consulting Department of Cystic Fibrosis Medical Genetic Science Center; Pediatrician, Department of Cystic Fibrosis Moscow Regional State Referral Center for Children

1 Moskvorech'e ul., Moscow, 115522, 

24a/1 Kominterna ul., Mytishchi, Moskovskaya oblast', 141009

Россия

A. Yu. Voronkova

Medical Genetic Science Center;
Moscow Regional State Referral Center for Children

Email: fake@neicon.ru

Anna Yu. Voronkova – MD, PhD, Senior Research Fellow, Clinical and Consulting Department of Cystic Fibrosis Medical Genetic Science Center; Pediatrician, Department of Cystic Fibrosis Moscow Regional State Referral Center for Children

1 Moskvorech'e ul., Moscow, 115522, 

24a/1 Kominterna ul., Mytishchi, Moskovskaya oblast', 141009

Россия

V. D. Sherman

Medical Genetic Science Center;
Moscow Regional State Referral Center for Children

Email: fake@neicon.ru

Viktoriya D. Sherman – MD, PhD, Senior Research Fellow, Clinical and Consulting Department of Cystic Fibrosis Medical Genetic Science Center; Pediatrician, Department of Cystic Fibrosis Moscow Regional State Referral Center for Children

1 Moskvorech'e ul., Moscow, 115522, 

24a/1 Kominterna ul., Mytishchi, Moskovskaya oblast', 141009

Россия

E. I. Kondratyeva

Medical Genetic Science Center;
Moscow Regional State Referral Center for Children

Email: fake@neicon.ru

Elena I. Kondratyeva – MD, PhD, Professor, Head of Clinical and Consulting Department of Cystic Fibrosis Medical Genetic Science Center; Head of Department of Cystic Fibrosis Moscow Regional State Referral Center for Children

1 Moskvorech'e ul., Moscow, 115522, 

24a/1 Kominterna ul., Mytishchi, Moskovskaya oblast', 141009

Россия

V. B. Chernykh

Medical Genetic Science Center;
Pirogov Russian National Research Medical University

Email: fake@neicon.ru

Vyacheslav B. Chernykh – MD, PhD, Head of Laboratory of Genetics of Reproductive Disorders Medical Genetic Science Center; Associate Professor, Chair of Molecular Genetics and Cytogenetics of Medicobiologic Faculty Pirogov Russian National Research Medical University

1 Moskvorech'e ul., Moscow, 115522, 

1 Ostrovityanovа ul., Moscow, 117997

Россия

References

  1. Красовский СА, Черняк АВ, Воронкова АЮ, Амелина ЕЛ, Каширская НЮ, Кондратьева ЕИ, Гембицкая ТЕ, ред. Регистр больных муковисцидозом в Российской Федерации. 2016 год. М.: Медпрактика-М; 2018. 64 с.
  2. Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell. 1993;73(7):1251–4. doi: 10.1016/0092-8674(93)90353-R.
  3. Капранов НИ, Каширская НЮ, ред. Муковисцидоз. М.: Медпрактика-М; 2014. 672 с.
  4. Castellani C, Cuppens H, Macek M Jr, Cassiman JJ, Kerem E, Durie P, Tullis E, Assael BM, Bombieri C, Brown A, Casals T, Claustres M, Cutting GR, Dequeker E, Dodge J, Doull I, Farrell P, Ferec C, Girodon E, Johannesson M, Kerem B, Knowles M, Munck A, Pignatti PF, Radojkovic D, Rizzotti P, Schwarz M, Stuhrmann M, Tzetis M, Zielenski J, Elborn JS. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. J Cyst Fibros. 2008;7(3):179–96. doi: 10.1016/j.jcf.2008.03.009.
  5. Pettit RS. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment. Ann Pharmacother. 2012;46(7–8):1065–75. doi: 10.1345/aph.1R076.
  6. Michl RK, Tabori H, Hentschel J, Beck JF, Mainz JG. Clinical approach to the diagnosis and treatment of cystic fibrosis and CFTR-related disorders. Expert Rev Respir Med. 2016;12:1–10. doi: 10.1080/17476348.2016.1240032.
  7. Петрова НВ, Тимковская ЕЕ, Зинченко РА, Гинтер ЕК. Анализ частоты некоторых мутаций в гене CFTR в разных популяциях России. Медицинская генетика. 2006;5(2): 28–31.
  8. Степанова АА, Красовский СА, Поляков АВ. Информативность поиска 19 частых мутаций в гене CFTR у российских больных муковисцидозом и расчетная частота заболевания в Российской Федерации. Генетика. 2016;52(2):231–41.
  9. Красовский СА, Петрова НВ, Степанова АА, Усачева МВ, Самойленко ВА, Амелина ЕЛ, Никонова ВС. Клиническое течение заболевания у взрослых больных муковисцидозом – носителей «мягких» мутаций. Пульмонология. 2012;(6):5–11. doi: 10.18093/0869-0189-2012-0-6-5-11.
  10. Черных ВБ. Ген муковисцидоза и нарушение фертильности у мужчин. Андрология и генитальная хирургия. 2010;11(4):23–32.
  11. Rowntree RK, Harris A. The phenotypic consequences of CFTR mutations. Ann Hum Genet. 2003;67(Pt 5):471–85. doi: 10.1046/j.1469-1809.2003.00028.x.
  12. Duguépéroux I, De Braekeleer M. The CFTR 3849+10kbC->T and 2789+5G->A alleles are associated with a mild CF phenotype. Eur Respir J. 2005;25(3):468–73. doi: 10.1183/09031936.05.10100004.
  13. Feldmann D, Couderc R, Audrezet MP, Ferec C, Bienvenu T, Desgeorges M, Claustres M, Mittre H, Blayau M, Bozon D, Malinge MC, Monnier N, Bonnefont JP, Iron A, Bieth E, Dumur V, Clavel C, Cazeneuve C, Girodon E. CFTR genotypes in patients with normal or borderline sweat chloride levels. Hum Mutat. 2003;22(4): 340. doi: 10.1002/humu.9183.
  14. Mickle JE, Cutting GR. Genotype-phenotype relationships in cystic fibrosis. Med Clin North Am. 2000;84(3):597–607. doi: 10.1016/S0025-7125(05)70243-1.
  15. Черных ВБ, Степанова АА, Бескоровайная ТС, Сорокина ТМ, Шилейко ЛВ, Курило ЛФ, Поляков АВ. Частота и спектр мутаций и IVS8-T-полиморфизма гена CFTR среди российских мужчин с бесплодием. Генетика. 2010;46(6):844–52.
  16. Claustres M. Molecular pathology of the CFTR locus in male infertility. Reprod Biomed Online. 2005;10(1):14–41. doi: 10.1016/S1472-6483(10)60801-2.
  17. Chen H, Ruan YC, Xu WM, Chen J, Chan HC. Regulation of male fertility by CFTR and implications in male infertility. Hum Reprod Update. 2012;18(6): 703–13. doi: 10.1093/humupd/dms027.
  18. Blau H, Freud E, Mussaffi H, Werner M, Konen O, Rathaus V. Urogenital abnormalities in male children with cystic fibrosis. Arch Dis Child. 2002;87(2):135–8. doi: 10.1136/adc.87.2.135.
  19. Radpour R, Gourabi H, Dizaj AV, Holzgreve W, Zhong XY. Genetic investigations of CFTR mutations in congenital absence of vas deferens, uterus, and vagina as a cause of infertility. J Androl. 2008;29(5):506–13. doi: 10.2164/jandrol.108.005074.
  20. Chillón M, Casals T, Mercier B, Bassas L, Lissens W, Silber S, Romey MC, Ruiz-Romero J, Verlingue C, Claustres M, et al. Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N Engl J Med. 1995;332(22):1475–80. doi: 10.1056/NEJM199506013322204.
  21. Llabador MA, Pagin A, Lefebvre-Maunoury C, Marcelli F, Leroy-Martin B, Rigot JM, Mitchell V. Congenital bilateral absence of the vas deferens: the impact of spermatogenesis quality on intracytoplasmic sperm injection outcomes in 108 men. Andrology. 2015;3(3):473–80. doi: 10.1111/andr.12019.
  22. Patat O, Pagin A, Siegfried A, Mitchell V, Chassaing N, Faguer S, Monteil L, Gaston V, Bujan L, Courtade-Saïdi M, Marcelli F, Lalau G, Rigot JM, Mieusset R, Bieth E. Truncating mutations in the adhesion G Protein-Coupled Receptor G2 Gene ADGRG2 Cause an X-linked congenital bilateral absence of vas deferens. Am J Hum Genet. 2016;99(2):437–42. doi: 10.1016/j.ajhg.2016.06.012.
  23. Marcorelles P, Gillet D, Friocourt G, Ledé F, Samaison L, Huguen G, Ferec C. Cystic fibrosis transmembrane conductance regulator protein expression in the male excretory duct system during development. Hum Pathol. 2012;43(3):390–7. doi: 10.1016/j.humpath.2011.04.031.
  24. Fok KL, Chen H, Ruan YC, Chan HC. Novel regulators of spermatogenesis. Semin Cell Dev Biol. 2014;29:31–42. doi: 10.1016/j.semcdb.2014.02.008.
  25. Xu WM, Chen J, Chen H, Diao RY, Fok KL, Dong JD, Sun TT, Chen WY, Yu MK, Zhang XH, Tsang LL, Lau A, Shi QX, Shi QH, Huang PB, Chan HC. Defective CFTR-dependent CREB activation results in impaired spermatogenesis and azoospermia. PLoS One. 2011;6(5):e19120. doi: 10.1371/journal.pone.0019120.
  26. Tanner JM, Whitehouse RH, Takaishi M. Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. I. Arch Dis Child. 1966;41(219): 454–71.
  27. Руководство ВОЗ по исследованию и обработке эякулята человека. 5-е изд., 2010 г. Пер. с англ. М.: Капитал Принт; 2012. 304 c.
  28. Rathaus V, Werner M, Freud E, Mei-Zahav M, Mussaffi H, Blau H. Sonographic findings of the genital tract in boys with cystic fibrosis. Pediatr Radiol. 2006;36(2):162–6. doi: 10.1007/s00247-005-0055-4.
  29. Hubert D, Patrat C, Guibert J, Thiounn N, Bienvenu T, Viot G, Jouannet P, Epelboin S. Results of assisted reproductive technique in men with cystic fibrosis. Hum Reprod. 2006;21(5): 1232–6. doi: 10.1093/humrep/dei453.
  30. Chiang HS, Lin YH, Wu YN, Wu CC, Liu MC, Lin CM. Advantages of magnetic resonance imaging (MRI) of the seminal vesicles and intra-abdominal vas deferens in patients with congenital absence of the vas deferens. Urology. 2013;82(2):345–51. doi: 10.1016/j.urology.2013.03.038.
  31. von Eckardstein S, Cooper TG, Rutscha K, Meschede D, Horst J, Nieschlag E. Seminal plasma characteristics as indicators of cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in men with obstructive azoospermia. Fertil Steril. 2000;73(6):1226–31. doi: 10.1016/S0015-0282(00)00516-1.
  32. Thorpe-Beeston JG. Contraception and pregnancy in cystic fibrosis. J R Soc Med. 2009;102 Suppl 1:3–10. doi: 10.1258/jrsm.2009.s19002.
  33. Leifke E, Friemert M, Heilmann M, Puvogel N, Smaczny C, von zur Muhlen A, Brabant G. Sex steroids and body composition in men with cystic fibrosis. Eur J Endocrinol. 2003;148(5): 551–7.
  34. Штаут МИ, Шилейко ЛВ, Репина СА, Красовский СА, Шмарина ГВ, Сорокина ТМ, Курило ЛФ, Черных ВБ. Комплексное сперматологическое обследование пациентов с муковисцидозом. Андрология и генитальная хирургия. 2017;18(4):69–76. doi: 10.17650/2070-9781-2017-18-4-69-76.
  35. Boyd JM, Mehta A, Murphy DJ. Fertility and pregnancy outcomes in men and women with cystic fibrosis in the United Kingdom. Hum Reprod. 2004;19(10):2238–43. doi: 10.1093/humrep/deh405.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Repina S.A., Krasovskiy S.A., Shmarina G.V., Shtaut M.I., Zhekayte E.K., Voronkova A.Y., Sherman V.D., Kondratyeva E.I., Chernykh V.B.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies